# Stage 3 Verification Pass — Against Stage 2's Output

Run per `requirements.md` §7's mandatory gate: Stage 2 does not close without this.

## Deterministic checks (`generator/clinical_consistency.py`)

0 findings across multiple runs (n=5,000-8,000, seeds 100/200). All four checks ran (no skipped checks — every field they depend on is present).

## LLM reviewer pass

Cross-tabs reviewed against Stage 2's changes specifically (Tier A recalibration, Tier B model, evidence_tier backfill):

| Check | Result |
|---|---|
| `chronic_pain` by `metastatic_disease` (No 4.63 / Yes 6.03) | Sensible gap, matches the literature-cited edge (`e_metastatic_disease_chronic_pain`, weight 1.5). |
| `depression_severity_index` (diagnosed) by `disease_stage` | Still fairly flat (~10.5-12.6 across stages) — **not new**, same pre-existing limitation documented earlier this session (ECOG's own weak stage-sensitivity dilutes the signal through the ADL/IADL-driven inhibitory edges into depression). Not worsened by Stage 2. |
| `cognitive_function_mmse` by `age_bracket` | Initially looked non-monotonic at n=8,000 (18-35: 19.47 < 36-55: 20.00) — investigated, confirmed as small-sample noise (18-35 is now only ~2.9% of the population post-recalibration). At n=30,000: correctly monotonic (20.15 / 20.05 / 19.07 / 17.85). |
| `fatigue`/`nausea_vomiting` by `has_chemo` | Modest, sensible gap (6.14→6.78 fatigue, 3.70→4.37 nausea), matches existing edge weights. |
| Male breast cancer rate | 0.04%, unaffected by Stage 2 (control check — this was a Stage-1-round fix, confirming it wasn't regressed). |
| Overall functional/psych stability (ADL 77.7, IADL 6.1, anxiety 6.74, suicidal_ideation_risk 3.23) | All within the healthy ranges established earlier this session — no new saturation or drift introduced by Stage 2's recalibration. |

**No new findings.** Stage 2 is clear to close.
